Details of the Drug Reposition

General Information of This Drug (ID: DM1874J)

Drug Name
TRC105   DM1874J
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Angiosarcoma DISIYS9W 2B56 Phase 3 [1]
------------------------------------------------------------------------------------
9 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 2 [2]
Soft tissue sarcoma DISSN8XB 2B57 Phase 2 [3]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 2 [4]
Peritoneal cancer DISYX23I 2C51.Z Phase 2 [5]
Ovarian cancer DISZJHAP 2C73 Phase 2 [5]
Fallopian tube cancer DISXHWCS 2C74 Phase 2 [5]
Renal cell carcinoma DISQZ2X8 2C90 Phase 2 [4]
Gestational trophoblastic neoplasia DIS4EJNA 2F33-2F76 Phase 2 [4]
Macular degeneration DISLKKHD 9B78.3 Phase 2 [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Indications(s)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lung cancer DISCM4YA 2C25.0 Phase 1 [4]
Breast cancer DIS7DPX1 2C60-2C65 Phase 1 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02979899) Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.